Extending the Time Window for Stroke Treatment: Advanced Brain Imaging ± Bat Saliva

1 Tissue plasminogen activator for acute ischemic stroke: The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581–7.

2 Parsons MW Barber PA Chalk J . Diffusion- and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol 2002; 51:28–37.

3 Warach S . Thrombolysis in stroke beyond three hours: targeting patients with diffusion and perfusion MRI. Ann Neurol 2002; 51:11–3.

4 Thomalla G Schwark C Sobesky J . Outcome and symptomatic bleeding complications of intravenous thrombolysis within 6 hours in MRI-selected stroke patients: comparison of a German multi-center study with the pooled data of ATLANTIS, ECASS, and NINDS tPA trials. Stroke 2006; 37:852–8.

5 Kohrmann M Juttler E Fiebach JB . MRI versus CT-based thrombolysis treatment within and beyond the 3 hour time window after stroke onset: a cohort study. Lancet Neurol 2006; 5:661–7.

6 Lansberg MG Thijs VN Hamilton S . Evaluation of the clinical-diffusion and perfusion-diffusion mismatch models in defuse. Stroke 2007; 38:1826–30.

7 Davis S Donnan GA . Breaking the 3 h barrier for treatment of acute ischaemic stroke. Lancet Neurol 2008; 7:981–2.

8 Nicole O Docagne F Ali C . The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 7:59–64.

9 Reddrop C Moldrich RX Beart FM . Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005; 36:1241–6.

10 Liberatore GT Samson A Bladin C Schleuning W-D Medcalf RL . Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34:537–43.

11 Hacke W Albers G Al-Rawi Y . The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36:66–73.

12 Furlan AJ Eyding D Albers GW . Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37:1227–31.

13 Warach Sfor the DIAS-2 Study Group. Clinical benefit of desmoteplase treatment in patients with moderate to severe stroke – further results of the DIAS-2 study. Presented at the 2008 International Stroke Conference. February 22, 2008. New Orleans, LA.